Objectives: Learning key points for treating Dark skin / Asian skin for better result with less complications.

Introduction: Asian skin are darker than Caucasian skin and are prone to have side effects or complications such as scars and PIH.

Materials / method: The topic of this session is "Lasers & EBD: challenging applications in dark skin/Asian patients".
Four presentations will give by four experts from Asian and Europe.

Results: This session will cover laser or EBD treatment of vascular and scar lesions; fractional laser and cosmeceuticals for pigmented lesions in darker skin patients; and using picosecond lasers for melasma in Asian patients.

Conclusion: Careful evaluation the patient and set reasonable treatment strategy which including the optimal energy setting, treatment interval, multidevice combination, adjuvant therapy and post-treatment care such as cosmeceuticals may promising better outcome for Asian patients.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: testestesttestestesttestestesttestestesttestestesttestestest

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: 1. Understand the histological changes by the 1064/532 fractional picosecond lasers.
2. Know the strategies of single or combination of different wavelengths for better outcome in the treatment of melasma

Introduction: Melasma is a troublesome pigmentary problem in Asians. Many treatment modalities are used to fight melasma, but none is the almighty solution. Although Q-switched 1064nm laser toning has good effects, complications such as mottled dyspigmentation would sometimes be encountered because of the accumulated photothermal damage to the melanocytes. Picosecond lasers have shorter pulse duration than the nanosecond lasers, which exerts more photomechanical effects with less photothermal damage. We want to find the better treatment strategy of using picesecond lasers for melasma.

Materials / method: For histology, we did skin biopsies for the fractional picosecond lasers with 1064nm and 532nm wavelengths. For clinical trial, we used single or combination of different wavelengths to treat melasma in Asian patients.

Results: Histologically, laser-induced optical breakdown (LIOB) took place above a certain threshold fluence both in 1064nm and 532nm fractional picosecond lasers. Clinically, treatment with 1064nm picotoning, or in combination with fractional 1064nm or 532nm handpieces, all gave good results.

Conclusion: Melasma in Asians can be treated by picosecond lasers with 1064nm picosecond laser toning monotherapy. There seems to be beneficial effects when it is combined with fractional 1064/532nm handpiece.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: testestesttestestesttestestesttestestesttestestest

Disclosures

Did you receive any funding to support your research for this TOPIC?
No
Please specify entities (individual, company, society): Syneron-Candela

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Syneron-Candela

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability